Storia dell'articolo
Chiudi
Questo articolo è stato pubblicato il 21 marzo 2013 alle ore 16:26.
Current annual funding for R&D devoted to TB is estimated to be $500 million. But more than $2 billion is needed annually. That amount may seem unrealistically high, but it is a negligible proportion of the estimated $160 billion spent on health-related R&D worldwide. More important, the economic burden of TB has been put as high as $20 billion annually – and even higher if the losses in human capital are included.
If we choose to continue suffering these losses, we might save some money in the short term. The wiser course, however, is to make the necessary investments today, thereby averting a much larger bill tomorrow.
Stefan H.E. Kaufmann is Professor of Immunology and Microbiology at the Charité University Clinics in Berlin and Founding Director of the Max Planck Institute of Infection Biology.
Copyright: Project Syndicate, 2013.
Clicca per Condividere
©RIPRODUZIONE RISERVATA
Permalink
Ultimi di sezione
-
Gli economisti
Perché preoccuparsi per la Francia?
di Paul Krugman
-
gli economisti
Krugman: il dibattito sull'austerity è politicizzato
di Paul Krugman
-
Italia
A Theory About European Naval Domination
di Paul Krugman
-
Italia
Una teoria sul predominio navale dell'Europa
di di Paul Krugman
-
IL PIANO JUNCKER
Gros: consumi prima che investimenti
di Daniel Gros
